Phase II clinical trial (paediatric oncology) — CINV prevention
Background
A Phase II clinical study was conducted in paediatric oncology to evaluate the efficacy of a new antiemetic intended to prevent chemotherapy-induced nausea and vomiting.
The trial was conducted over several treatment cycles, requiring rigorous follow-up of paediatric patients and careful management of safety and efficacy data.
Challenges identified
The study presented several operational challenges:
- • recruitment of a paediatric population, which is often limited and calls for heightened ethical vigilance,
- • management of multi-cycle chemotherapy follow-up, requiring close coordination between medical and research teams,
- • and rigorous collection of patient symptom diaries, essential to ensure the reliability of the clinical assessment.
Pharmaspecific’s role
Pharmaspecific provided monitoring and quality follow-up in France, ensuring the completeness of safety and efficacy data.
The team also supported investigator sites with documentation and process compliance, ensuring the study ran smoothly and in line with regulatory requirements.
Results
These results enabled a robust assessment of the efficacy and tolerability of the investigational treatment.
Key takeaways
This project illustrates the ability of Pharmaspecific to work on sensitive paediatric studies, where data quality and reliability are decisive.
The experience gained strengthens its expertise in paediatric oncology, particularly in managing multicentre trials that require rigorous oversight and a human approach adapted to young patients.